Published by
@ShahidNShah
@ShahidNShah
Mindstrong’s Demise and The Future of Mental Health Care
Mindstrong, once a promising mental health startup, recently announced its closure despite raising $160 million. Initially a biomarker-focused AI company, it shifted to app-based mental health care but struggled with financial viability. In the U.S. health system, the challenge lies in valuing mental health until payment is involved. The focus on technology in mental health should address systemic underinvestment. Reimbursement realities, a complex coding system, and profit-centric healthcare contribute to service gaps. As long as insurers inadequately compensate mental health services, the cost-effectiveness of treating mental health issues remains unfulfilled. The closure highlights the need for comprehensive payment reform advocacy.
Medigy Insights
Mindstrong's closure, despite raising $160 million, underscores challenges in the U.S. mental health landscape. Initially an AI biomarker company, it shifted to app-based mental health care, revealing a systemic issue: Americans prioritize mental health until facing payment. The focus on technology over systemic reform and reimbursement realities contribute to ongoing service gaps. The underinvestment in mental health services, driven by profit-centric healthcare, persists even in highly-ranked institutions. As long as insurers inadequately compensate mental health, cost-effective treatment remains a distant goal. Mindstrong's fate signals the need for comprehensive payment reform advocacy and renewed focus on mental health.
Continue reading at statnews.com
Make faster decisions with community advice
- Insitro, Biotech AI’s quiet Unicorn, Unveils Efforts in ALS, Liver Disease, and Cancer at JPM
- JPM24: Innovaccer Joins AI Scribe Race, Unveiling Tool to Simplify Note-Taking For Doctors
- Amazon Takes on Health Systems With New Care Management Program
- FDA's Robert Califf on AI in Healthcare: 'It's a Different World'
- How Wellstar MCG Built A Long -Term Virtual Care Strategy
Next Article
-
Insitro, Biotech AI’s quiet Unicorn, Unveils Efforts in ALS, Liver Disease, and Cancer at JPM
Insitro, a leading biotech AI company, steps into the limelight, unveiling groundbreaking initiatives in ALS, liver disease, and cancer at the JPMorgan Healthcare Conference. Despite the buzz around …
